Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
The importance of coronaviruses as human pathogen has been highlighted by the recent outbreak of SARS-CoV-2 leading to the search of suitable drugs to overcome respiratory infections caused by the virus. Due to the lack of specific drugs against coronavirus, the existing antiviral and antimalarial drugs are currently being administered to the patients infected with SARS-CoV-2. The scientists are also considering repurposing of some of the existing drugs as a suitable option in search of effective drugs against coronavirus till the establishment of a potent drug and/or vaccine. Computer-aided drug discovery provides a promising attempt to enable scientists to develop new and target specific drugs to combat any disease. The discovery of novel targets for COVID-19 using computer-aided drug discovery tools requires knowledge of the structure of coronavirus and various target proteins present in the virus. Targeting viral proteins will make the drug specific against the virus, thereby, increasing the chances of viral mortality. Hence, this review provides the structure of SARS-CoV-2 virus along with the important viral components involved in causing infection. It also focuses on the role of various target proteins in disease, the mechanism by which currently administered drugs act against the virus and the repurposing of few drugs. The gap arising from the absence of specific drugs is addressed by proposing potential antiviral drug targets which might provide insights into structure-based drug development against SARS-CoV-2.
Computational drug discovery, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Drug repurposing, Computational Drug Discovery, Pharmaceutical Science, Antiviral Agents, Article, Clinical trials, Drug Delivery Systems, Síndrome respiratorio agudo grave, Drug Development, Target proteins, Drug Discovery, Humans, Computer Simulation, Pandemics, SARS-CoV-2, Drug Repositioning, Proteins, COVID-19, Computational Biology, COVID-19 Drug Treatment, Coronavirus, Coronavirus Infections
Computational drug discovery, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Drug repurposing, Computational Drug Discovery, Pharmaceutical Science, Antiviral Agents, Article, Clinical trials, Drug Delivery Systems, Síndrome respiratorio agudo grave, Drug Development, Target proteins, Drug Discovery, Humans, Computer Simulation, Pandemics, SARS-CoV-2, Drug Repositioning, Proteins, COVID-19, Computational Biology, COVID-19 Drug Treatment, Coronavirus, Coronavirus Infections
44 Research products, page 1 of 5
- 2018IsRelatedTo
- 2018IsRelatedTo
- 2005IsRelatedTo
- 2020IsRelatedTo
- 2020IsRelatedTo
- 2011IsRelatedTo
- 2019IsRelatedTo
- 2003IsRelatedTo
- 2020IsRelatedTo
- 2020IsRelatedTo
chevron_left - 1
- 2
- 3
- 4
- 5
chevron_right
41 bioentities, page 1 of 3
chevron_left - 1
- 2
- 3
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).27 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
